Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Sep. 2, 1998

Banyu presents urea derivatives with NPY receptor-antagonist activity

Sep. 2, 1998

L-168721: potent, nonpeptide GH secretagogue

Sep. 2, 1998

P&U to market Glyset in U.S., Canada and several other countries

Sep. 2, 1998

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

Sep. 2, 1998

Novartis continues to study DPP IV inhibitors; new lead reported at ACS meeting

Sep. 1, 1998

Novo Nordisk describes the first nonpeptide competitive glucagon antagonist

Sep. 1, 1998

Androsorb to enter second part of hormone replacement therapy trial

Sep. 1, 1998

New ACAT inhibitors synthesized at Sumitomo

Aug. 31, 1998

Columbia Laboratories develops hormone replacement tablet for men

Aug. 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...